Intrommune in the News

February 2021

Global Data publishes profile of Intrommune Therapeutics’ Phase Ib study and its Series B raise

January 2021

Intrommune presentation at the H.C. Wainwright BioConnect 2021 Conference by Dr. Abhit Singh

December 2020

William Reisacher, MD’s article in Coping with Allergies & Asthma: Five Things you Should Know about Peanut Allergy Immunotherapy

November 2020

Intrommune CEO, Michael Nelson, spoke with PetaCrunch about Intrommune’s approach to treating peanut allergies

October 2020

Intrommune selected as Semifinalist in the Innovate Children’s Health Challenge

March 2020

Senior Medical Advisor, William Reisacher, interviewed on the Price of Business with Kevin Price

January 2020

Proactive Interview: Intrommune Therapeutics moving its peanut allergy treatment through the FDA approval process

September 2019

Providing Innovative Treatments for Peanut Allergies
Intrommune CEO, Michael Nelson, interview on the Price of Business with Kevin Price

September 2019

Science News: Liquid mouth drops could one day protect people from peanut allergies

Octoberber 2018

Intrommune Therapeutics selected as one of the RESI NYC Innovation Challenge Finalists

July 2018

Intrommune Senior Scientific Advisor, Dr. Reisacher, featured in SELF article: Southwest Airlines Is Finally Getting Rid of In-Flight Peanuts

June 2018

Q&A with Michael Nelson, JD, Co-Founder and CEO of Intrommune Therapeutics
developing a revolutionary new Drug Delivery method using Toothpaste to
Deliver an Oral Mucosal Immunotherapy for People who have a Peanut Allergy

May 2018

New Idea for Immunotherapy–an Interview with Dr. Toothpaste